VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Ten Flabbergasting Costs of America’s Obesity Epidemic

Several new drugs could also help in addressing the obesity epidemic. VIVUS, Inc. (NASDAQ:VVUS) currently markets weight-loss pill Qsymia. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shouldn’t be too far behind. The company received Food and Drug Administration approval for its drug, Belviq, but is awaiting final scheduling by the Drug Enforcement Administration. Contrave, a weight-loss pill from Orexigen Therapeutics, Inc. (NASDAQ:OREX), is still in a late-stage clinical study but could hit the market next year if ultimately approved.

Let’s hope that these and other solutions make a difference. The costs if they don’t are enormous.

The article 10 Flabbergasting Costs of America’s Obesity Epidemic originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.